Aventis Pasteur deploys CB Technologies's MetaTrial EDC to speed multiple clinical trials
According to CB Technologies MetaTrial EDC is designed to enable companies to increase efficiencies in their clinical trial data collection process enabling them to reduce time to market for biological products in development.
"After evaluating several EDC systems, we selected CB's MetaTrial for its
hybrid architecture and ease of use," said Richard Fritz, Director, IS
Research to Launch Process at Aventis Pasteur. "Our Clinical Operations/IS
Team evaluated various EDC systems, and we concluded that CB Technologies'
provided a high quality EDC solution with a technical staff for exceptional
customer support. As we analyzed user feedback from our study sites, we
learned that investigators found the MetaTrial system easiest to use."
In addition, CB Technologies revealed MetaTrial Hybrid will allow Aventis Pasteur to provide its study sites with an EDC system that investigators can rely on to operate in any
telecommunications environment.
"Aventis Pasteur joins a growing number of premiere global pharmaceutical, biotech and CRO organizations that are turning to CB's hybrid EDC to ensure that sites have an EDC system that
consistently works when they need it to work," said Rusty Beardsley, CB's Senior Vice President, Sales and Marketing. "CB's MetaTrial Hybrid ensures that work can always continue under even the most challenging telecommunications environments. Additionally, CB's array of
services-training, help desk, hosting-allows companies such as Aventis Pasteur to more easily adopt EDC by relying on CB's expertise in rolling out electronic clinical trials, training personnel and building studies quickly and efficiently."